Cargando…
An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
BACKGROUND: Interferon (IFN) beta drugs have been approved for the treatment of relapsing forms of multiple sclerosis (RMS) for more than 20 years and are considered to offer a favourable benefit-risk profile. In July 2014, subcutaneous (SC) peginterferon beta-1a 125 μg dosed every 2 weeks, a pegyla...
Autores principales: | Kolb-Mäurer, Annette, Sunderkötter, Cord, Kukowski, Borries, Meuth, Sven G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570848/ https://www.ncbi.nlm.nih.gov/pubmed/31202258 http://dx.doi.org/10.1186/s12883-019-1354-y |
Ejemplares similares
-
Interdisciplinary research: putting the methods under the microscope
por: Robertson, David W, et al.
Publicado: (2003) -
Victims and/or perpetrators? Towards an interdisciplinary dialogue on child soldiers
por: Derluyn, Ilse, et al.
Publicado: (2015) -
Jack-of-all-trades, master of none: Postgraduate perspectives on interdisciplinary health research in Australia
por: Carey, Gemma E, et al.
Publicado: (2007) -
Brucellosis remains a neglected disease in the developing world: a call for interdisciplinary action
por: Franc, K. A., et al.
Publicado: (2018) -
Curbing the lifestyle disease pandemic: making progress on an interdisciplinary research agenda for law and policy interventions
por: Toebes, Brigit, et al.
Publicado: (2017)